Lilly ads for dog drug misleading, U.S. FDA says

(Reuters) - Lilly's materials touted the percentage of dogs that improved with Reconcile compared with a placebo, but failed to mention that both groups received behavior modification training, the FDA letter said. The promotions "suggest that the product is more effective than has been demonstrated," the FDA said.



The materials also did not mention that some dogs improved with the behavioral training alone, according to the FDA.


Read more at Reuters.com Government Filings News